Skip to main content

Table 2 Immunoexpression of luminal and basal markers in the bladder cancer cohort

From: Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression

  GATA3 and FOXA1 − GATA3 and/or FOXA1 +
 WHOLE COHORT
  CK5/6 − 4 (3.1%) 66 (52.4%)
  CK5/6 + 5 (4.0%) 51 (40.5%)
 NMIBC
  CK5/6 − 1 (2.0%) 30 (58.8%)
  CK5/6 + 1 (2.0%) 19 (37.2%)
 MIBC
  CK5/6 − 3 (4.2%) 35 (48.6%)
  CK5/6 + 4 (5.5%) 30 (41.7%)
  1. MIBC muscle invasive bladder cancer, NMIBC non-muscle invasive bladder cancer